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Catherine T. Jordan,1 Li Cao,1 Elisha D.O. Roberson,1 Katherine C. Pierson,2 Chi-Fan Yang,3
Cailin E. Joyce,1 Caitriona Ryan,4 Shenghui Duan,1 Cynthia A. Helms,1 Yin Liu,5 Yongqing Chen,5
Alison A. McBride,6 Wuh-Liang Hwu,7 Jer-Yuarn Wu,3 Yuan-Tsong Chen,3 Alan Menter,4,8
Raphaela Goldbach-Mansky,5,8 Michelle A. Lowes,2,8 and Anne M. Bowcock1,*
Psoriasis is a common, immune-mediated genetic disorder of the skin and is associated with arthritis in approximately 30% of cases.
Previously, we localized PSORS2 (psoriasis susceptibility locus 2) to chromosomal region 17q25.3-qter after a genome-wide linkage
scan in a family of European ancestry with multiple cases of psoriasis and psoriatic arthritis. Linkage to PSORS2 was also observed in
a Taiwanese family with multiple psoriasis-affected members. In caspase recruitment domain family, member 14 (CARD14), we identi-
fied unique gain-of-function mutations that segregated with psoriasis by using genomic capture and DNA sequencing. The mutations
c.349G>A (p.Gly117Ser) (in the family of European descent) and c.349þ5G>A (in the Taiwanese family) altered splicing between
CARD14 exons 3 and 4. A de novoCARD14mutation, c.413A>C (p.Glu138Ala), was detected in a child with sporadic, early-onset, gener-
alized pustular psoriasis. CARD14 activates nuclear factor kappa B (NF-kB), and compared with wild-type CARD14, the p.Gly117Ser and
p.Glu138Ala substitutions were shown to lead to enhancedNF-kB activation and upregulation of a subset of psoriasis-associated genes in
keratinocytes. These genes included chemokine (C-C motif) ligand 20 (CCL20) and interleukin 8 (IL8). CARD14 is localized mainly in
the basal and suprabasal layers of healthy skin epidermis, whereas in lesional psoriatic skin, it is reduced in the basal layer and more
diffusely upregulated in the suprabasal layers of the epidermis. We propose that, after a triggering event that can include epidermal
injury, rare gain-of-function mutations in CARD14 initiate a process that includes inflammatory cell recruitment by keratinocytes.
This perpetuates a vicious cycle of epidermal inflammation and regeneration, a cycle which is the hallmark of psoriasis.Introduction
Psoriasis is a poorly understood common inflammatory
disorder of the skin and other organs and affects approxi-
mately 2% of individuals of European descent.1 It can be
associated with a chronic inflammatory psoriatic arthritis
in ~30% of affected individuals.2 Genome-wide associa-
tion studies (GWASs) have identified over 20 susceptibility
loci for psoriasis,3–11 but less than 20% of disease variance
is explained.12,13 Additional low-risk loci, genetic interac-
tions, or rare variants of large effect are thought to account
for the remaining disease variance. It is difficult to identify
the latter, but they are expected to be observed in rare fami-
lies in which psoriasis segregates as a Mendelian trait.
Seventeen years ago, we mapped psoriasis susceptibility
locus 2 (PSORS2 [MIM 602723]) to human chromosomal
region 17q25-qter in a single large family (PS1) of Euro-
pean ancestry.14 The region of linkage spanned 3.5 Mb
from D17S784 to 17qter. Affected members had plaque
psoriasis, and approximately 30% also developed psoriatic
arthritis. Two additional genome-wide linkage scans
further implicated PSORS2. A study of 224 sibling pairs
with psoriasis yielded a maximum LOD score of 2.09
with D17S802,15 and a five-generation psoriasis pedigree
from Taiwan exhibited significant linkage to D17S928.16
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segregated as an autosomal-dominant Mendelian trait
with high penetrance.
To identify the familial mutations, we attempted associ-
ation studies and extensive resequencing of genes under
the linkage peak.17–19 Recently, we included targeted and
exome capture followed by NextGen sequencing of DNA
from members of family PS1 and identified in caspase
recruitment domain family, member 14 (CARD14 [MIM
607211])20 a mutation that segregated with psoriasis. We
then identified a second CARD14 mutation in the 17q25-
linked Taiwanese family, and a young child with severe
generalized pustular psoriasis (PSORP [MIM 614204])
harbored a de novo mutation within CARD14. Wild-type
CARD14 activates nuclear factor-kappa B (NF-kB), and
the psoriasis-associated missense mutations further upre-
gulate NF-kB activity. Compared with wild-type keratino-
cytes, cultured keratinocytes from affected individuals
with the mutations and a keratinocyte cell line transfected
with mutant CARD14 showed increased transcription of
genes encoding psoriasis-associated chemokines and cyto-
kines such as interleukin 8 (IL8 [MIM 146930]), chemokine
(C-C motif) ligand 20 (CCL20 [MIM 601960]), and inter-
leukin 36, gamma (IL36G [MIM 605542]). CARD14
peptides in the skin were almost exclusively localized in
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of the epidermis. Compared with normal skin, psoriatic
skin showed reduced levels of CARD14 in the basal layer
but increased levels throughout the upper layers. We
propose that, in the context of an inflammatory stimulus,
keratinocytes harboring the CARD14 mutations can upre-
gulate an inflammatory response via excessive activation
of NF-kB-responsive genes and initiate the recruitment of
the inflammatory infiltrate seen in psoriasis. Our findings
resolve the identity of the elusive PSORS2 locus and iden-
tify CARD14 as a regulator of skin inflammation.Subjects and Methods
Subjects
Family PS1 of European origin and the 17q25-linked Taiwanese
psoriasis-affected family are described elsewhere.14,16 The person
with pustular psoriasis (individual 2192) was a 3-year-old child
from Haiti. Her father, mother, and brother were unaffected, and
there was no family history of psoriasis or any other autoimmune
disorder. Whole blood was obtained by venipuncture; skin
samples were obtained by punch biopsy. Primary keratinocytes
from family PS1 and classical-psoriasis cases were immortalized
by infection with human papillomavirus E6/E7 DNA (a gift from
Dr. Denise Galloway at the Fred Hutchinson Center for Cancer
Research).21 Keratinocytes from individual 2192, who has pustular
psoriasis, and two foreskin samples used as controls were immor-
talized without transformation as previously described.22 Proto-
cols were approved by local institutional review boards (IRBs).
All subjects or their parents (if the subjects were minors) provided
informed consent.
Genomic Capture and Sequence Analysis
Exome capture and targeted capture of the 17q25 linkage region
were performed with DNA from family PS1 and were followed
by NextGen sequencing. For exome sequencing, DNA from four
affected individuals was used. For targeted capture, pools of
genomic DNA from 14 affected and eight unaffected samples
were used. Genomic libraries were prepared with the Illumina
Paired-End Genomic DNA Sample Prep Kit. Genomic capture
was performed with Roche-Nimblegen SeqCap EZ Exome and
Agilent SureSelect Target Enrichment kits. Captured DNA was
sequenced on the Illumina Genome Analyzer II (GAIIx) for 76
cycles (one lane per sample or pool). Both capture methods signif-
icantly enriched the targeted regions (Table S1, available online).
Read Mapping and Sequence Analysis
Read mapping, sequence analysis, and variant calling were per-
formed as described elsewhere.23 Known polymorphisms (variants
in dbSNP130 and eight previously sequenced HapMap individ-
uals) were excluded.24 Candidate mutations in the 17q25 linkage
region were those observed in at least three of the four exomes
sequenced and/or observed in the affected pool but not in the
unaffected pool. Mutations were manually annotated for amino
acid changes and were Sanger sequenced for validation and for
checking segregation with disease (Table S2).
Minigene Assay
CARD14 minigenes were constructed by PCR amplification of
human genomic DNA from unaffected (wild-type) and affected
members of family PS1 (affected by c.349G>A) and the TaiwaneseThe Amfamily (affected by c.349þ5G>A). PCR fragments included
CARD14 exon 3 and 150 bp each of the 50 and 30 introns. Frag-
ments were digested by BamH1 and XbaI and were ligated into
the RHCglo vector (a gift from Dr. Tom Cooper at the Baylor
College of Medicine) at the corresponding digest sites. All
constructs were validated with DNA sequencing. Minigene
constructs were used as described previously.25 Minigenes were
transfected into human embryonic kidney (HEK) 293 cells. Total
RNA was harvested after 24 hr. cDNA was synthesized with the
SuperScript II kit (Invitrogen) and the RTRHC oligonucleotide
primer 50-GGGCTTTGCAGCAACAGTAAC-30. Using the TNIE4
50-AGGTGCTGCCGCCGGGCGGTGGCTG-30 and RSV5U 50-CAT
TCACCACATTGGTGTGC-30 primers, we sequenced the cDNA to
evaluate the splicing of CARD14 exon 3 in the presence of the
familial psoriasis mutations and in the presence of the reference
CARD14 sequence. Sequencing primers were those described
above as well as an internal exon 3 primer, 50-ACTTGCTGGAT
TTGCTGAAGAC-30.
Expression Plasmids
The pNFkB-luc plasmid (Clontech) contains the firefly luciferase
gene and four tandem copies of the consensus NF-kB-binding
sequence fused to a TATA-like promoter. The pTAL-luc plasmid
(Clontech) contains an enhancerless reporter with a minimal
TATA-like promoter and the firefly luciferase gene, and it was
used as a negative control.
Two CARD14 cDNA clones, CARD14sh (coding for 740 amino
acids; GenBank BC018142) and CARD14cl (coding for 434 amino
acids; RefSeq NM_052819) were used (Capital Biosciences). A full-
length (CARD14fl) construct was not available. Mutant forms of
CARD14 were prepared from the CARD14sh construct (GenBank
BC018142) with the QuikChange Site-Directed Mutagenesis Kit
(Stratagene).
NF-kB Luciferase Reporter Assay
HEK 293 cells were cultured under standard conditions and plated
at a density of 0.15 million cells per well in 12-well plates. Cells
were cotransfected with (1) 0.5 mg wild-type CARD14sh or the
CARD14cl expression construct, (2) 0.5 mg pTAL-luc or pNF-kB-
luc plasmid, and (3) 0.025 mg pGL4.70 Renilla reporter plasmid
(Promega). In total, 1.025 mg of plasmid DNA was transfected
into each cell. For cotransfections, 0.5 mg of each CARD14
construct was transfected into cells. Then, 0.05 mg of pGL4.70
and 0.5 mg of reporter plasmid were added for a total of 1.55 mg
plasmid DNA transfected into each cell. All transfections were per-
formed in triplicate. For stimulation with TNF-a (tumor necrosis
factor alpha [encoded by TNF (MIM 191160)]), cells were treated
with 20 ng/ml TNF-a in culture medium. For TNF-a neutralization
experiments, cells were treated with indicated concentrations of
TNF-a neutralizing antibody (Cell Applications). Cells were
harvested 24 hr after transfection, and firefly luciferase activity
was determined with the Dual-Luciferase Reporter Assay System
(Promega). We normalized firefly luciferase activity to Renilla lucif-
erase activity to control for transfection efficiency. Relative NF-kB
luciferase activity for each sample was then calculated by back-
ground subtraction of pTAL luciferase activity and the subsequent
division of the normalized NF-kB luciferase value by the back-
ground pTAL luciferase value.
Expression Profiling
HEK 001 cells (human-papillomavirus-16-transformed keratino-
cytes) were transfected with wild-type CARD14sh or mutanterican Journal of Human Genetics 90, 784–795, May 4, 2012 785
(c.349G>A [p.Gly117Ser] or c.413A>C [p.Glu138Ala]) CARD14sh
expression constructs. Cells were cultured for 24 hr, after which
time total RNA was isolated. Lesional and nonlesional skin biop-
sies from an affected member (GEN001) of family PS1 were ob-
tained from the Psoriasis Research Institute (Dallas, Texas), and
a lesional skin biopsy from child 2192, who has severe pustular
psoriasis, was obtained from the National Institute of Arthritis
and Musculoskeletal and Skin Diseases. Biopsies of normal skin
(n ¼ 2) and moderate-to-severe lesional psoriasis skin (n ¼ 2)
were obtained from Rockefeller University for global expression
profiling. RNA was extracted from full-thickness skin biopsies.
Immortalized keratinocyte lines from uninvolved skin of affected
members (K1-1 and K1-20) of family PS1 and from involved skin of
classical psoriasis (K5-14, an HLA-Cw*0602-positive case) were
cultured with or without stimulation by TNF-a, and total RNA
was isolated. Immortalized, nontransformed keratinocytes from
individual 2192 and from two foreskin samples were cultured in
medium only. For all samples described above, total RNA isolation
was performedwith themiRNeasy or RNeasy kit (QIAGEN). Global
expression profiling was performed with HumanHT-12 v4 Expres-
sion BeadChip (Illumina). For each BeadChip (Illumina), at least
0.2 mg of total RNA per sample was reverse transcribed, amplified,
and labeled. Experiments were conducted in compliance with
MIAME (minimum information about a microarray experiment)
guidelines. Raw and normalized expression data are deposited in
the National Center for Biotechnology Information (NCBI) Gene
Expression Omnibus (GEO) with accession number GSE36387.
For expression analyses, data were imported into R (v2.13.1)
with the BeadArray (v2.2.0) package. Raw data were used for anal-
ysis. For single-sample-by-single-sample comparisons, probes that
did not show a detection p value < 0.05 in any sample were
excluded. The average signal, standard error, and number of beads
were used for the computation of a two-sample, two-sided t test
assuming unequal variance. Fold-changes were calculated on
the basis of the average expression values. We adjusted p values
with the Benjamini and Hochberg method to control for false
discovery.
For group-wise comparisons, average expression values were
quantile normalized and log2 transformed. Contrasts for each
desired class comparison were created with Limma (v3.8.3). Probe
expression values were modeled as linear models, and statistics for
fold-changes and p values were calculated on these models with
the limma ‘‘eBayes’’ function. p values were adjusted as described
above.
CARD14 Transcript Isoform Analysis
cDNA Cloning and Sequencing
SuperScript II (Invitrogen) was used for the generation of cDNA
from RNA derived from the involved skin of individual GEN001.
PCR-based cloning of the exon 2–4 region of CARD14 was per-
formed according to standard protocols with exon-2- and exon-
4-specific oligonucleotide primers (50-AGGAGACACTGTGGGAG
ATGAT-30 for exon 2 and 50-ATTGCTATAGTGCAGCGAGAGG-30
for exon 4). Plasmid inserts were sequenced with the same oligo-
nucleotide primers.
Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) was performed in routine fashion
on total RNA primed with randomhexamer oligonucleotides. PCR
reactions were performedwith Power SYBR Greenmaster mix (Life
Technologies) on a 7900HT thermocycler (Life Technologies).
Expression was normalized to 18S rRNA. Relative expression
levels were calculated according to the 2-DDCt method as follows:786 The American Journal of Human Genetics 90, 784–795, May 4, 22 3 106((Ct 18S)(Ct CARD14)). We corrected for differences in trans-
fection efficiency by normalizing expression levels in transfected
cells to levels of FLAG. Primers for the transcripts examined by
qRT-PCR are available upon request.
Immunohistochemistry
Normal skin samples (n ¼ 3–4) and paired uninvolved and
involved psoriatic samples (n ¼ 5–6) were obtained from Rockefel-
ler University from individuals with mild-to-severe stable plaque
psoriasis. PS1 uninvolved and involved skin was collected and
studied under a protocol approved by the IRB at Washington
University. All frozen sections were stained with polyclonal rabbit
anti-CARD14 (Sigma, 1:600). This antibody labels the internal
coiled-coil domain of CARD14 and recognizes all known isoforms.
Secondary biotin-labeled goat anti-rabbit antibodies (Vector
Laboratories) were used. The staining signal was amplified with
avidin-biotin complex (Vector Laboratories) and developed with
chromogen 3-amino-9-ethylcarbazole (Sigma Life Sciences). The
negative control was stained with 1% serum in lieu of the primary
antibody.Results
Exome- and Targeted-Sequencing Results
Family PS1 is of European ancestry and has multiple
cases of psoriasis and psoriatic arthritis.14 DNA of family
members was used for exome sequencing, targeted-capture
sequencing, and NextGen sequencing. Only the following
two protein-coding mutations were identified in the ~3.5
Mb linkage region and segregated with the disease (Tables
S1 and S2): c.349G>A (p.Gly117Ser) in CARD14 and
c.365A>G (p.Tyr122Cys) in solute carrier family 26,
member 11 (SLC26A11 [MIM 610117]) (Figures 1A and 1B
and Table S2). Numbering of all CARD14 mutations in
this manuscript is based on RefSeq NM_024110.3.
Numbering of the SLC26A11 mutation is based on RefSeq
NM_001166347.1. CARD14, also known as CARMA2,
encodes a member of the CARMA (caspase recruitment
domain [CARD]- and membrane-associated guanylate
kinase [MAGUK]) family; this member interacts with
BCL10 and activates NF-kB.20 SLC26A11 encodes a
sulfate/anion transporter.26 Bothmutations were predicted
to be potentially damaging by PolyPhen-2.027 and SIFT.28
Further Evidence of CARD14 Mutations Predisposing
to Psoriasis
Coding exons and flanking intronic DNA of CARD14
and SLC26A11 were resequenced in affected members of
the Taiwanese psoriasis-affected family.16 This revealed
a c.349þ5G>A mutation in CARD14 but none in
SLC26A11. Resequencing of 54 members of this family
(21 affected, 20 unaffected, and 13 of unknown disease
status) demonstrated that this mutation segregated with
psoriasis (Figure 1C). This family had previously been
sequenced for all genes under the linkage peak, and only
one other possible disease-causing variant, a mutation
upstream of the transcriptional start site of zinc finger
protein 750 (ZNF750 [MIM 610226]), had been identified
(discussed further below).19012
Figure 1. Positional Cloning of PSORS2 and Mutations Segregating in Linked Families
(A) Location of PSORS2 showing polymorphic microsatellites D17S784 and D17S982 and the locations of CARD14 and SLC26A11 and
familial mutations. The following abbreviation is used: SGSH, N-sulfoglucosamine sulfohydrolase (MIM 605270).
(B) The pedigree of family PS1 shows genotypes at mutated loci (phased as displayed) of CARD14 (c.349G>A; upper) and SLC26A11
(c.365A>G; lower). The unaffected woman with an asterisk recently developed psoriasis at 83 years of age. The affected male labeled
GEN001 provided skin biopsies of uninvolved and involved (psoriatic plaque) skin used for this study.
(C) The pedigree of 17q25-linked Taiwanese psoriasis-affected family shows genotypes of the c.349þ5G>Amutation in familymembers.
Black-filled symbols indicate classical psoriasis. Gray-filled symbols indicate mild skin manifestation of psoriasis. Question marks indi-
cate unknown disease status.
(D) Both familial CARD14mutations are located within the consensus splice donor sequence of exon 3. Chromatograms obtained after
resequencing of this splice donor sequence in DNA of an affected member of each family are shown. The exon-intron junction is indi-
cated by the vertical black line. The two mutations are boxed in red.We also identified a de novo germline mutation
(c.413A>C [p.Glu138Ala]) in exon 4 of CARD14 in a
3-year-old Haitian child (individual 2192) who had severe
pustular psoriasis since the age of 6 months (Figures 2A–
2C). The mutation was predicted to be damaging by Poly-
Phen-2.027 and SIFT.28 The child had no family history of
psoriasis or any other inflammatory disorder. She did not
harbor any mutation in SLC26A11 nor the interleukin 36
receptor antagonist (IL36RN [MIM 605507]), a gene
recently described to be mutated in pustular psoriasis.32,33
Neither the multiplex families nor the child with
pustular psoriasis harbored the PSORS1 risk variant, HLA-
Cw*0602,34 suggesting that CARD14 mutations are suffi-
cient to lead to disease. None of these mutations were
detected in the sequences of the 1,000 Genomes Project,35
dbSNP130, or in eight previously exome-sequenced
HapMap individuals.24 They were also shown to be present
in the psoriatic population at very low frequencies (<0.1%
of cases) and to be even less frequent or absent in controls
(see the accompanying paper36 in this issue of AJHG).The AmFamilial Psoriasis Mutations Alter Splicing of Exon 3
The CARD14 nucleotides mutated in the two families and
in the pustular case were highly conserved in vertebrates
(Figure 2D). The amino acids altered in family PS1 and
individual 2192 with pustular psoriasis were also highly
conserved (Figure S1). Although the p.Gly117Ser substitu-
tion was a missense alteration, the fact that both familial
mutations lie in the splice donor sequence of exon 3
suggests that they might affect splicing (Figure 1D). We
investigated this with in vitro splicing assays (Figures 3A
and 3B),25 which revealed that both familial mutations
lead to the use of a cryptic splice donor site 66 bp from
the start of intron 3 (AG/GTGCCC, Figures 3B and 3C).
This caused an insertion of 22 amino acids into the
CARD14 peptide between exons 3 and 4 (Figure 3D).
We were also interested in evaluating the effects of these
mutations in vivo. Although RNA and cDNA from the skin
of affected members of the Taiwanese family were unavail-
able, we obtained a skin biopsy and extracted cDNA from
the skin of an affected member (GEN001) of family PS1.erican Journal of Human Genetics 90, 784–795, May 4, 2012 787
Figure 2. Detection of a De Novo
CARD14 Mutation in an Individual with
Pediatric Pustular Psoriasis and Conserva-
tion of Mutated Nucleotides
(A) Child 2192, who has pustular psoriasis,
before treatment. Most of the body is
covered with lesions.
(B) Sequence traces for 2192 and her
parents revealing a de novoCARD14muta-
tion, c.413A>C (p.Glu138Ala).
(C) The pedigree of individual 2192 shows
parental genotypes for de novo mutation
c.413A>C (p.Glu138Ala).
(D) Alignment of DNA sequences from
the indicated species is shown for the
segments of CARD14 exon 3, intron 3,
and exon 4 harboring the CARD14 muta-
tions described here. The mutations are
shown in red and are marked with aster-
isks. DNA and protein sequences were
downloaded from the UCSC Genome
Browser29 and were aligned with Clus-
talW2.30,31 The genome builds used for
each species are as follows: hg19 (human),
panTro2 (chimp), rheMac2 (rhesus), mm9
(mouse), bosTau4 (cow), canFam2 (dog),
monDom5 (opossum), fr2 (fugu), gasAcu1
(stickleback), and oryLat2 (medaka).cDNA sequencing with primers amplifying transcripts
between exons 2 and 4 of CARD14 from skin of this indi-
vidual revealed the presence of low levels of a correctly
spliced mutant c.349A allele transcript (Figure S2A) and
an isoform with splicing directly from exon 2 to exon 4
(e.g., skipping of exon 3; Figure S2B).
We performed further analyses of wild-type and mutant
CARD14 transcripts from the exon 2–4 region by using
RNA-Seq employing RNA from involved skin from
GEN001. This revealed that 47% of CARD14 transcripts
harbored the wild-type c.349G allele and that 12% of tran-
scripts harbored the c.349A allele with correct splicing
between exons 3 and 4. 9% of transcripts harbored the
66 bp intronic insertion (predicted by the minigene assay)
between exons 3 and 4. We also identified 17% of the tran-
scripts that were due to the skipping of exon 3 (presumably
as a result of the c.349A mutation). Similar ratios of wild-
type and mutant transcripts of each type were seen after
PCR-based cloning and sequencing of cDNA spanning
exons 2–4 (Figure S3 and Table S3).
However, RNA-Seq revealed an additional RNA species
that could not be identified with PCR-based amplification
of cDNA. This species extended from exon 3 into the
intron and terminated 838 bp downstream (Figure S3
and Table S3). This mRNA isoform was confirmed to be
from the sense strand of CARD14 (Figure S4). It was repre-
sented by ~15% of all transcripts and would encode a
peptide of an additional 59 amino acids after exon 3 and
a 30UTR of 656 bp. This transcript would be predicted
to encode only the CARD domain. This peptide could ex-
hibit constitutive CARD14-induced activation of NF-kB
or exert a dominant-negative effect on wild-type CARD14.
Additional studies are needed if researchers are to deter-788 The American Journal of Human Genetics 90, 784–795, May 4, 2mine its effect as well as the contribution of the other
mutant species to psoriasis pathogenesis. Nevertheless,
additional functional studies (described below) indicated
that the c.349A canonically spliced transcript itself has
gain-of-function activity and is likely to contribute to
disease. RNA-Seq with RNA derived from normal skin or
classical (nonfamilial) psoriatic skin only revealed correctly
spliced CARD14 transcripts between exons 3 and 4 (Figures
S3 and S4 and Table S3).
Effect of Mutations on CARD14 Function In Vitro
CARD14 encodes a 1,004 amino acid protein that activates
NF-kB20 and is represented by several isoforms. Full-length
CARD14 (CARD14fl, also known as CARD14 isoform 1)
encodes both an N-terminal CARD domain necessary
for activation of NF-kB and a C-terminal tripartite
MAGUK domain (PDZ/SH3/GUK).18 A shorter isoform,
CARD14sh, encodes the CARD domain but not the tripar-
tite domain. Another isoform, CARDcl, lacks the CARD
domain and the tripartite domain (these latter isoforms
lacking the tripartite domain are both known as isoform
2; Figure S5). Interrogation of a human tissue panel
revealed that CARD14sh was the most abundant isoform
in all tissues, including skin, in which it was expressed
(Table S4).
We used luciferase reporter assays to test the effects of
the familial and pustular-psoriasis substitutions on the
NF-kB-inducing activity of the abundant CARD14sh pro-
tein isoform. Expression constructs with the p.Gly117Ser
and p.Gly138Ala substitutions were generated, and an
expression construct encoding CARD14cl, which lacks
the CARD domain, served as a negative control for NF-kB
activation. A construct encoding the full-length CARD14fl012
Figure 3. Familial CARD14 Mutations Alter Splicing of Exon 3
(A) The CARD14 exon 3 minigene constructs are wild-type, c.349G>A (mutation in the northern European PS1 family), and
c.349þ5G>A (mutation in the Taiwanese psoriasis-affected family). The vertical line indicates the junction of exon 3 and the intron
of CARD14. The following abbreviation is used: RSV, Rous sarcoma virus promoter.
(B) Results of agarose gel electrophoresis after transfection of minigenes and isolation of cDNA. Mutant minigene PCR products were
60–70 bp larger than those of the wild-type construct. The following abbreviations are used: Non-tx, nontransfected; Vector,
RHCglo25 vector alone; and WT, wild-type minigene. c.349G>A and c.349þ5G>A are the mutant minigenes.
(C) Results of sequencingminigenes. Minigene c.349þ5G>A is shown. Bothmutations altered splicing of exon 3 and led to the addition
of 66 bp from intron 3 and splicing to exon 4 at a cryptic splice donor site (AG/GTGCCC). The following abbreviation is used: sTN1,
chicken skeletal troponin I (RHCglo23 downstream gene fragment).
(D) Consequence of altered splicing on CARD14.protein isoform was not available for subcloning into the
expression vector.
The NF-kB assay revealed that compared with wild-type
CARD14sh, both substitutions lead to increased levels of
the luciferase reporter. The pustular-psoriasis substitution
(p.Glu138Ala) led to a 7- to 9-fold increase in levels, and
the PS1 p.Gly117Ser substitution led to a 3- to 4-fold
increase in levels (Figure 4B). CARD14cl failed to activate
NF-kB, in agreement with previous studies.20,37 We also
investigated the dominant nature of the substitutions
by cotransfecting wild-type and either p.Glu138Ala or
p.Gly117Ser CARD14sh constructs and performing the
NF-kB luciferase reporter assay. The resultant NF-kB
activity was similar to that seen with the p.Glu138Ala
and p.Gly117Ser substitutions alone (Figure 4B), providing
additional evidence of their gain-of function activity.
Cotransfection of CARD14cl and CARD14sh caused
NF-kB activity to be reduced by approximately 50% as
a result of either a dilution of CARD14sh or a dominant-
negative effect of CARD14cl (Figure 4B).The AmBecause TNF-a activates NF-kB pathways, it was impor-
tant to ascertain whether the increase in NF-kB activity
seen in some of our assays was due to TNF-a secreted by
transfected cells. The addition of a neutralizing TNF anti-
body did not have an effect on NF-kB reporter activity
(Figure S6). These results support the disease-causing
potential of the familial and de novo pustular-psoriasis
substitutions through activation of the NF-kB pathway.
Tissue-Specific Localization of CARD14
To examine the localization of CARD14 in healthy and
psoriatic skin, we stained normal and psoriatic skin
samples with a polyclonal antibody specific to the coiled-
coil domain of CARD14 (Figure 5). Staining of basal kerati-
nocytes was observed in normal and uninvolved skin, and
decreased expression was seen in the upper layers of the
skin, including the granular layer. This contrasted with
involved skin, in which there was loss of labeling of basal
keratinocytes but labeling throughout the remainder of
the epidermis and of some dermal cells. There was reduced,erican Journal of Human Genetics 90, 784–795, May 4, 2012 789
Figure 4. Location of CARD14 Alterations and Their Effect on Transcriptional Activation
(A) The location of the familial alterations and the de novo substitution in CARD14 are shown relative to the key protein domains. The
two familial alterations are shown by blue triangles; the pustular-psoriasis alteration is shown by the purple triangle.
(B) NF-kB activation levels measured in HEK 293 cells transfected with one of four options: (1) CARD14sh alone, (2) the same construct
harboring one of the rare variants shown, (3) CARD14cl, or (4) a combination of two constructs from options 1–3. The change in NF-kB
activity relative to the background vector was determined for each variant (y axis) (see Subjects and Methods). Every data point repre-
sents the average value of three replicates. Asterisks represent results from a two-tailed, unpaired student’s t test between the indicated
construct and CARD14sh. The NF-kB activity induced by cotransfection of the p.Gly117Ser substitution and wild-type CARD14sh was
not statistically significant from the NF-kB activity induced by CARD14sh alone (p ¼ 0.1) or p.Gly117Ser alone (p ¼ 0.7).
(C) HEK 001 cells were transfected with wild-type or altered (c.349G>A [p.Gly117Ser] or c.413A>C [p.Glu138Ala]) CARD14sh,
and qRT-PCR was performed so that the upregulation of CCL20, IL8, SOD2, and IL36G identified by global expression profiling
could be confirmed. Asterisks represent results from a two-tailed, unpaired student’s t test between the indicated construct and
CARD14sh.
(D) Upregulation of those same transcripts was confirmed in primary keratinocytes of individual 2192 with pustular psoriasis (c.413A>C
[p.Glu138Ala]). Expression in these primary keratinocytes was compared with that in two human foreskin keratinocyte samples (control
1 and control 2). For all qRT-PCR, expression levels were normalized to 18S by the 2-DDCt method. For the transformation of expression
levels to nondecimal integers, all expression levels weremultiplied by 100,000 before being plotted on graphs. Asterisks represent results
from a two-tailed, unpaired student’s t test between the indicated control and the mutant (p.Glu138Ala). For (B–D), error bars represent
the standard deviation of replicates, and *p% 0.05, **p% 0.01, and ***p% 0.001. The following abbreviations are used: NT, nontrans-
fected; G117S, p.Gly117Ser; E138A, p.Glu138Ala; and Ctrl, control.patchy epidermal labeling in involved skin of GEN001
(Figures 5A and 5B and Figure S7). Although there might
be a subset of dermal immune cells that express CARD14,
keratinocytes are clearly a major source of CARD14.
Previous mRNA-expression studies have reported
elevated levels (a 2.7-fold increase) of CARD14 in involved
psoriatic skin versus uninvolved skin.38 We have con-
firmed this with qRT-PCR (not shown). However, our
data indicate that this apparent increase in gene expression
might be due to an increase in the ratio of CARD14-posi-
tive keratinocytes to CARD14-negative keratinocytes in
involved skin rather than an increase in the number of
CARD14 transcripts at the cellular level.790 The American Journal of Human Genetics 90, 784–795, May 4, 2Effect of CARD14 Substitutions on Keratinocyte
Gene Expression
CARD14 localizes strongly to epidermal keratinocytes (see
above), suggesting that the effect of the substitutions is
mediated at least in part through this cell type. We there-
fore investigated the effect of wild-type and altered
CARD14 (p.Gly117Ser and p.Glu138Ala) on the transcrip-
tome of psoriatic skin and keratinocytes separately.We per-
formed global expression profiling of classical psoriatic
skin, skin from an affected member (GEN001) of family
PS1, and skin from individual 2192 with pustular psoriasis,
and we compared transcript levels with those from normal
skin. We also profiled HEK 001 immortalized keratinocytes012
Figure 5. Distribution of CARD14 in Normal
and Psoriatic Skin
Representative images of normal and psoriatic
(uninvolved and involved) skin labeled with
a polyclonal antibody to the internal coiled-coil
CARD14 domain that is shared by all known iso-
forms.
(A) Normal skin and classical uninvolved and
involved psoriasis skin.
(B) A normal-skin negative control and unin-
volved and involved affected skin from indi-
vidual GEN001 from family PS1. The epidermis
is the darker-stained upper band (black arrow),
and the dermis is the paler region below. The
black line denotes the dermoepidermal junction;
lesional skin is cut on a slight cross section, and
the dermis is evident as islands projecting
upwards into the epidermis. The scale bar repre-
sents 100 mm.that had been transfected with a wild-type CARD14sh
construct or a CARD14sh construct encoding one of the
missense substitutions (p.Gly117Ser or p.Glu138Ala). We
then looked for genes that were upregulated in psoriatic
skin and that were expressed at significantly higher levels
in the p.Glu138Ala and p.Gly117Ser transfectants than
in the wild-type-CARD14sh transfectants (Table S5).
A number of transcripts consistently showed increased
expression in psoriatic skin, upregulation after keratino-
cytes were transfected with CARD14sh, and further
upregulation in the presence of the p.Glu138Ala and
p.Gly117Ser substitutions. This was confirmed with qRT-
PCR (Figure 4C). For example, in the presence of the
p.Glu138Ala and p.Gly117Ser substitutions, CCL20 was
upregulated 7.23 and 1.93 more, respectively, and IL8
was upregulated 4.63 and 1.63 more, respectively, than
in the presence of wild-type CARD14sh. The p.Glu138Ala
substitution increased expression of superoxide dismutase
2, mitochondrial (SOD2 [MIM 147460]) and IL36G
4.13 and 1.83 more, respectively, than did wild-type
CARD14sh (Table S5 and Figure 4C). We also confirmed
upregulation of these transcripts in primary keratinocytes
from individual 2192 with pustular psoriasis (Figure 4D;
primary keratinocytes from family PS1 were not available).
As a complement to these studies, we also profiled three
immortalized keratinocyte lines before and after treatment
with TNF-a. Two lines were from uninvolved skin of
affected members (K1-1 and K1-20) of family PS1, and
the other was from involved skin of a classical-psoriasis-
affected individual (K5-14) who harbors the HLA-Cw*0602
risk allele. In all three immortalized keratinocyte lines,
TNF-a stimulation led to upregulation of the same tran-
scripts described above. All of this provided evidence that
after an inflammatory trigger, these transcripts are induced
in keratinocytes of affected members of family PS1 and of
classical-psoriasis-affected individuals (Table S5).
It is also relevant that compared with those of normal
skin, the transcriptomes of involved skin from the
familial, pustular-psoriasis, and classical-psoriasis samples
exhibited very similar differences. This suggests that path-The Amways downstream of CARD14 can be similarly altered
in classical, pustular, and familial psoriasis. Table S6
provides fold changes of transcripts that most strongly
differentiate classical psoriasis from normal skin, as well
as fold changes of the same transcripts in involved skin
from GEN001 (PS1) and the child, 2192, with pustular
psoriasis.Discussion
Here, rare, highly penetrant mutations in CARD14 have
been shown to cause psoriasis, thus concluding a 17 year
search for PSORS2.14 We identified two disease-causing
CARD14 mutations in two multiplex psoriasis-affected
families (c.349G>A [p.Gly117Ser] in family PS1 of
northern European ancestry and c.349þ5G>A in a family
from Taiwan). In the European family, approximately 30%
of affected members also had psoriatic arthritis, indicating
that the c.349G>A (p.Gly117Ser) mutation might also
contribute to inflammatory joint disease. Both of the
familial mutations disrupted splicing of CARD14 and
lead to an in-frame insertion of 22 amino acids in vitro.
The c.349G>A mutation was confirmed in vivo to lead to
multiple splice forms, including the 22 amino acid inser-
tion predicted from the minigene assay, another with
skipping of exon 3, and a third with the addition of 59
amino acids from intron 3 and a subsequent termination
signal and 661 bp 30UTR. The latter is predicted to result
in a truncated peptide with only the CARD domain. A
de novo mutation (c.413A>C [p.Glu138Ala]) in exon 4
of CARD14 in a child with sporadic, severe, early-onset
pustular psoriasis and no family history or susceptibility
factors for psoriasis independently confirmed the disease-
causing potential of these mutations. Interestingly, exon
4 encodes part of the coiled-coil domain of the protein.
A recessive mouse mutation in the coiled-coil domain of
a structurally related scaffold protein, CARD11, leads
to an inflammatory skin phenotype resembling atopic
dermatitis. This suggests that the coiled-coil domains oferican Journal of Human Genetics 90, 784–795, May 4, 2012 791
CARD14 and related family members are important in
regulating inflammation.39
The identification of a CARD14 mutation in the Taiwa-
nese family settles a paradox that existed between the
two multiplex psoriasis-affected families. The Taiwanese
family harbors a variant (c.625A>C in the promoter of
ZNF750) that was thought to cause psoriasis.19 However,
we identified no disease-causing mutation in ZNF750 in
the PS1 family, and we found the ZNF750 c.625A>C
variant in only 2 out of 172 healthy Asian controls. Hence,
the CARD14 mutation rather than the ZNF750 variant is
probably causative for psoriasis in this family.
It is also worth noting that one PS1 family member who
harbored the c.349G>A (p.Gly117Ser) mutation was
initially unaffected when ascertained in 199314 but devel-
oped psoriasis 17 years later at 83 years old (indicated by
the asterisk in Figure 1B). It is unknown which precipi-
tating factors contribute to this variable age of onset, but
genetic background40 and environmental factors are likely
to play a role. Determining whether the SLC26A11 variant
that cosegregated with psoriasis in family PS1 contributes
to psoriasis or psoriatic arthritis independently needs
further investigation.
A substantial proportion of individuals with psoriasis
have no family history of the disease. This has been
thought to be due to a requirement for environmental trig-
gers and/or inheritance ofmultiple low-risk genetic factors.
Until now, evidence implicating de novo mutations as
being causative in psoriasis or other common disease for
which there is no family history has been lacking. How-
ever, the early age of onset of severe generalized pustular
psoriasis in a child with a de novo mutation indicates
that such rare variants can account for some of these cases.
The frequency of de novo mutations contributing to
common diseases such as psoriasis is of interest, and genes
harboring such variants are expected to be identified at an
increasing rate now that global sequencing of DNA from
parents and affected children is feasible.
The role of CARD14 in health and disease remains to be
fully determined. It encodes a 1,004 amino acid protein
that activates the transcription factor NF-kB20 and inhibits
apoptosis.37 It has not been implicated previously in psori-
asis pathogenesis.CARD14 is expressed in the placenta and
mucosal surfaces,20,37,41 and, as demonstrated here, in the
keratinocytes of normal and inflamed skin. The localiza-
tion pattern of CARD14 differs between normal and
involved lesional skin. We show that it is localized in the
basal layer of the skin and is absent from the upper layers,
including the granular layer of normal skin, but the oppo-
site is true of psoriatic skin. In psoriatic skin, CARD14 is
absent from the basal layer and is present in all suprabasal
layers. This difference in expression pattern cannot be
easily explained. However, it highlights intrinsic differ-
ences between keratinocytes of healthy and psoriatic skin.
Although variants in CARD14 have not been described
previously in psoriasis, genetic alterations in components
of the NF-kB pathway are implicated from GWASs.5–11792 The American Journal of Human Genetics 90, 784–795, May 4, 2Moreover, basal-level constitutively active phosphorylated
NF-kB/RelA is found in uninvolved skin and is upregulated
in psoriasis plaques.42 Uncontrolled NF-kB activation has
also been suggested as the inflammatory pathway in
a recently published monogenic form of pustular psoriasis
caused by mutations in IL36RN.32,33 Our findings suggest
that in psoriasis, NF-kB-pathway alterations implicated
from GWASs can occur at the level of the keratinocyte as
well as at the level of the cells of the hematopoietic system.
Both of the missense substitutions reported here signifi-
cantly increased NF-kB activation and led to upregulation
of psoriasis-associated transcripts such as IL8 and CCL20.
The pustular-psoriasis substitution also led to upregulation
of IL36G and SOD2. TNF-a stimulation of epidermal kerati-
nocytes has previously been reported to lead to upregula-
tion of many genes, including IL8, CCL20, and SOD2,
harboring NF-kB binding sites in their promoters.43–45
These transcripts are also notable because of the functions
of the proteins they encode. IL8 is a well-known neutro-
phil chemotaxin,46 and CCL20 is a chemotactic factor
for CCR6þ immature dendritic cells and T cells. IL36G is
a proinflammatory cytokine, and SOD2 is a potential anti-
necroptosis gene.47 All of these molecules have been
shown to be upregulated in keratinocytes in response to
injury,48 suggesting that CARD14 mediates an important
conserved pathway that is triggered in response to disrup-
ted homeostasis (due to injury, infection, etc.) of the skin.
The effect of the pustular mutation on gene expression was
generally greater than that of the family PS1 mutation in
transfected keratinocytes. This might reflect an increased
severity in the presence of certain mutations such as
c.413G>A (p.Glu138Ala). However, it might be due in
part to the fact that we were unable to assay the combined
effect of the c.349G>A (p.Gly117Ser) mutation with all of
the in-frame, altered splice forms that occur as a result of
this mutation (and that are also predicted as a consequence
of the Taiwanese psoriasis mutation). Indeed, the relative
frequency of the splice forms might influence the severity
of disease as well as the effect of the missense p.Gly117Ser
substitution on NF-kB activation.
The expression alterations seen in keratinocytes with the
PS1 and pustular mutations allow us to propose a model of
psoriasis pathogenesis. After an inflammatory trigger that
might include infection and/or epidermal injury,48 a subset
of CARD14 substitutions that are found in psoriasis
patients induce enhanced activation of NF-kB. This leads
to pathologic levels of transcripts of some target genes,
including key chemokines implicated in psoriasis, such
as IL8 and CCL20. We suggest that the release of these
inflammatory mediators leads to the recruitment and
differentiation of inflammatory cells. Activated dendritic
cells then produce IL-23, a critical factor for Th17 develop-
ment, and T cells produce IL17 and IL22, leading to further
keratinocyte activation and epidermal hyperplasia.49 The
activation of keratinocytes and expression of IL36G also
induce the activation of the NF-kB pathway in inflamma-
tory cells and the further production of cytokines and012
Figure 6. ProposedModel of Psoriasis Pathogenesis in the Pres-
ence of Psoriasis-Specific CARD14 Alterations
After an inflammatory trigger, alterations in CARD14 induce activa-
tion of NF-kB. This leads to the transcription of many genes,
including key chemokines such as CCL20, IL8, and IL36G, impli-
cated in psoriasis. The proteins encoded by these transcripts can
recruit immune cells involved in disease pathogenesis. Those cells,
in turn,producecytokinesandchemokines that cause inflammation
and lead to further keratinocyte activation and epidermal hyper-
plasia (see Discussion). Other proteins in the NF-kB pathway have
been previously implicated in psoriasis and might be important in
CARD14 signaling to NF-kB. These proteins include A20,50 TNIP1,8
and Act1,5,6,9 and these, in turn, implicate TRAF2, TRAF3, and
TRAF6.37 IL36RN, recently found tobemutated inpustular psoriasis,
might also play a role in this pathway by inhibiting IL36g-induced
immune cell activation.32,33 All of these events contribute to this
vicious cycle of inflammation and acanthosis seen in psoriasis.chemokines. This creates a vicious cycle of inflammation
and acanthosis that characterizes psoriasis (Figure 6).
Notably, GWASs have identified psoriasis-associated alter-
ations at other loci harboring genes encoding members
of the NF-kB pathway. For example, variants near TNFAIP3
(tumor necrosis factor, alpha-induced protein 3, [TNFAIP3
(MIM 191163)]) are associated with psoriasis. That gene
encodes the protein A20, which negatively regulates NF-
kB activation by the CARD14-related peptides CARD11
and CARD10.50 TNIP1 (TNFAIP3-interacting protein 1,
[TNIP1 (MIM 607714)]) might also be involved in this
process because it acts in concert with A20 and is downre-
gulated in psoriatic skin.8 Although future studies are
needed for the dissection of the interaction between
CARD14 and the NF-kB pathway, we know that CARD14-
induced activation of NF-kB is dependent on TRAF2
and might also require TRAF3 or TRAF6.37 Thus, one
can hypothesize that activation of the CARD14-NF-kB
pathway might be downstream of Act1, encoded by
TRAF3IP2 (TRAF3-interacting protein 2, [TRAF3IP2 (MIM
607043)]), whichharbors a variant associatedwithpsoriasis
and psoriatic arthritis.5,6,9 Alternatively, CARD14 might
be part of a parallel pathway leading to NF-kB activation.
Loss-of-function amino acid substitutions in IL36RN wereThe Amrecently identified in some cases of pustular psoriasis.32,33
This protein directly opposes the activity of IL36g and
also intersects with the NF-kB pathway. Determining
whether and where activation pathways for CARD14 and
IL36RN intersect requires further evaluation.
Finally, our findings highlight the shortcomings of tradi-
tional schemes for classifying human disease on the basis
of clinical observations and underscore the utility of adapt-
ing molecular classification schemes based on the physi-
ology that is dysregulated in disease. In this instance,
common plaque psoriasis, pustular psoriasis, and, possibly,
psoriatic arthritis, represent different parts of a disease
severity spectrum and might all be ascribed to mutations
in the same gene (CARD14). Our findings also pave the
way for novel therapeutic interventions for these diseases.Supplemental Data
Supplemental Data include seven figures, six tables, and supple-
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